Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC
Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.
Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses a phase III trial that compared dovitinib (FGFR inhibitor) to sorafenib (VEGF inhibitor) for patients with metastatic renal cell carcinoma (mRCC) following prior treatment with one VEGF inhibitor and one mTOR inhibitor.
The primary endpoint of the trial was progression-free survival (PFS) with a total enrollment of 570 patients. Given the large size of the trial, an analysis of overall survival was also plausible, Grünwald states. In the trial, the median PFS was found to be 3.7 months with dovitinib compared to 3.6 months with sorafenib (HR = 0.86; P = .063). The median OS was 11.1 and 11.0 months in the dovitinib and sorafenib, respectively (HR = 0.96; P = .357).
Overall, these results indicate a negative trial, states Grünwald. However, since this is the first phase III trial specifically in the third-line setting, Grünwald believes the results support the use of sorafenib in this space.
<<<
